# 1 Identification of potential novel combination antibiotic regimens based on drug-

- 2 susceptibility and genetic diversity of Gram-negative bacteria causing neonatal sepsis in
- 3 low- and middle-income countries
- 4

Authors: Biljana Kakaraskoska Boceska<sup>1</sup>, Tuba Vilken<sup>1</sup>, Basil Britto Xavier<sup>1,2</sup>, Christine 5 Lammens<sup>1</sup>, Sally Ellis<sup>3</sup>, Seamus O'Brien<sup>3</sup>, Renata Maria Augusto da Costa<sup>3</sup>, Aislinn Cook<sup>4</sup>, Neal 6 Russell<sup>4</sup>, Julia Bielicki<sup>4</sup>, Eitan Naaman Berezin<sup>5</sup>, Emmanual Roilides<sup>6</sup>, Maia De Luca<sup>7</sup>, Lorenza 7 Romani<sup>7</sup>, Daynia Ballot<sup>8</sup>, Angela Dramowski<sup>9</sup>, Jeannette Wadula<sup>10</sup>, Sorasak Lochindarat<sup>11</sup>, 8 Suppawat Boonkasidecha<sup>11</sup>, Flavia Namiiro<sup>12</sup>, Hoang Thi Bich Ngoc<sup>13</sup>, Tran Minh Dien<sup>13</sup>, Tim 9 R. Cressey<sup>14</sup>, Kanchana Preedisripipat<sup>15</sup>, James A. Berkley<sup>16,17,18</sup>, Robert Musyimi<sup>19</sup>, 10 Charalampos Zarras<sup>20</sup>, Trusha Nana<sup>21</sup>, Andrew Whitelaw<sup>22</sup>, Cely Barreto da Silva<sup>23</sup>, Prenika 11 Jaglal<sup>24</sup>, Willy Ssengooba<sup>25</sup>, Samir K. Saha<sup>26</sup>, Mohammad Shahidul Islam<sup>26</sup>, Marisa Marcia 12 Mussi-Pinhata<sup>27</sup>, Cristina Gardony Carvalheiro<sup>27</sup>, Laura Piddock<sup>3</sup>, Surbhi Malhotra-Kumar<sup>1</sup>, 13

14 Michael Sharland<sup>4</sup>, Youri Glupczynski<sup>1</sup>, Herman Goossens<sup>1</sup>

15

# 16 Affiliations:

- <sup>17</sup> <sup>1</sup>Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of
- 18 Antwerp, Antwerp, Belgium
- 19 <sup>2</sup>STI unit, Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium
- <sup>3</sup>Global Antibiotic Research and Development Partnership (GARDP), Geneva, Switzerland
- <sup>4</sup>Center for Neonatal and Pediatric Infection & Immunity, St. George's University of London,
- 22 London, United Kingdom
- <sup>5</sup>Pediatric Infectious Diseases Unit, Santa Casa de Sao Paulo, Sao Paulo, Brazil
- <sup>6</sup>Infectious Diseases Unit, 3rd Dept Pediatrics, School of Medicine, Faculty of Health Sciences,
- 25 Aristotle University and Hippokration General Hospital, Thessaloniki, Greece
- <sup>26</sup> <sup>7</sup>Infectious Disease Unit, Bambino Gesu Children's Hospital, Rome, Italy
- <sup>8</sup>Department of Pediatrics and Child Health, School of clinical Medicine, Faculty of health
- 28 Sciences, University of the Witwatersrand, Johannesburg, South Africa
- <sup>9</sup>General Pediatrics, Tygerberg Hospital, Cape Town, South Africa
- 30 <sup>10</sup>Chris Hani Baragwanath Hospital Microbiology Laboratory, National Health Laboratory
- 31 Services, Johannesburg, South Africa
- 32 <sup>11</sup>Queen Sirikit National Institute of Child Health, Bangkok, Thailand
- <sup>12</sup>Mulago Specialized Women's and Neonatal Hospital, Kampala, Uganda

- <sup>13</sup>Vietnam National Children's Hospital, Hanoi, Vietnam
- <sup>14</sup>Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand
- 36 <sup>15</sup>Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand
- <sup>16</sup>Clinical Research Department, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
- <sup>17</sup>Centre for Tropical Medicine & Global Health, Nuffield Department of Medicine, University
- 39 of Oxford, Oxford UK
- 40 <sup>18</sup>The Childhood Acute Illness & Nutrition (CHAIN) Network, Nairobi, Kenya
- 41 <sup>19</sup>Department of Microbiology, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
- 42 <sup>20</sup>Microbiology Department, Hippokration General Hospital, Thessaloniki, Greece
- 43 <sup>21</sup>Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa
- 44 <sup>22</sup>Bristol Medical School, Bristol, United Kingdom
- 45 <sup>23</sup>Infection Control and Prevention Service, Santa Casa de Sao Paulo, Sao Paulo, Brazil
- 46 <sup>24</sup>Department of Medical Microbiology, National Health Laboratory Services, School of
- 47 Laboratory Medicine and Medical Science, University of KwaZulu-Natal, Durban, South Africa
- 48 <sup>25</sup>Makerere University, Department of Medical Microbiology, Kampala, Uganda
- 49 <sup>26</sup>Child Health Research Foundation (CHRF), Dhaka Shishu Hospital, Dhaka, Bangladesh
- <sup>27</sup>Department of Pediatrics, Ribeirao Preto Medical School, University of Sao Paulo, Brazil

#### 52 Abstract

**Objectives:** Several recent studies highlight the high prevalence of resistance to multiple antibiotic classes used in current treatment regimens for neonatal sepsis and new treatment options are urgently needed. We aimed to identify potential new combination antibiotic treatment regimens by investigating the drug-resistance and genetic profiles of the most frequently isolated Gram-negative bacteria causing neonatal sepsis in low- and middle-income countries (LMICs) in the NeoOBS study.

59

Material and methods: Gram-negative bacteria isolated from neonates with culture-confirmed sepsis from 13 clinical sites in nine countries, mainly LMICs, were analyzed. Culture-based identification was followed by whole-genome sequencing (WGS). Minimal inhibitory concentrations (MICs) for 8 antibiotics were determined for a representative subset of 108 isolates.

65

**Results:** Five bacterial species, *Klebsiella pneumoniae* (n=135), *Acinetobacter baumannii* 66 (n=80), Escherichia coli (n=34), Serratia marcescens (n=33) and Enterobacter cloacae complex 67 68 (ECC) (n=27) accounted for most Gram-negative bacterial isolates received (309/420, 74%). 69 Extended-spectrum  $\beta$ -lactamases (ESBL) genes mostly belonging to CTX-M-15 were found in 107 (79%) K. pneumoniae isolates and 13 (38%) E. coli, as well as in 6 (18%) and 10 (37%) S. 70 71 marcescens and ECC isolates, respectively. Carbapenem resistance genes were present in 41 (30%) K. pneumoniae, while 73 (91%) of A. baumannii isolates were predicted to be MDR based 72 on carbapenem resistance genes. Apart from A. baumannii, in which two major pandemic 73 74 lineages predominated, a wide genetic diversity occurred at the intraspecies level with different 75 MDR clones occurring at the different sites. Phenotypic testing showed resistance to the WHO first- and second- line recommended treatment regimens: 74% of K. pneumoniae isolates were 76

77	resistant to gentamicin and 85% to cefotaxime; E. coli isolates showed resistance to ampicillin,
78	gentamicin and cefotaxime in 90%, 38% and 47%, respectively. For the novel antibiotic regimens
79	involving different combinations of flomoxef, fosfomycin and amikacin, the overall predicted
80	MIC-determined susceptibility for Enterobacterales isolates was 71% (n=77) to flomoxef-
81	amikacin, 76% (n=82) to flomoxef-fosfomycin and 79% (n=85) to fosfomycin-amikacin
82	combinations, compared to 31% and 22% isolates susceptible to ampicillin-gentamicin and
83	cefotaxime, respectively. ESBL-producing Enterobacterales isolates were 100% susceptible both
84	to flomoxef-fosfomycin and flomoxef-amikacin and 92% to fosfomycin-amikacin.
85	
86	Conclusion: Enterobacterales carried multiple resistance genes to cephalosporins, carbapenems
87	and aminoglycosides. ESBL-producing K. pneumoniae and E. coli isolates were highly
88	susceptible to the three new antibiotic combination regimens planned to be evaluated in the
89	currently recruiting GARDP-sponsored NeoSep1 trial.
90	
91	Key words: Gram-negative bacteria, neonatal sepsis, new combination antibiotic regimens,
92	AMR, low- and middle-income countries (LMICs).

93

## 94 Introduction/Background

In 2019, more than 560,000 neonatal deaths were associated with bacterial antimicrobial
resistance (AMR), including nearly 140,000 deaths directly attributable to bacterial AMR [1].
The World Health Organization (WHO) reports that over 80% of these sepsis deaths could be
prevented if there was improved treatment and infection prevention [2].

Most of these cases occur in low- and middle-income countries (LMICs) [3]. Of the multiple 99 large studies recently conducted in these countries [1, 4-6], one systematic review [7] and several 100 single-site reports [8-10] have shown that Gram-negative bacteria (GNB), such as Klebsiella 101 102 spp., Escherichia coli and Acinetobacter baumannii, are considered the main cause of neonatal sepsis in approximately 40% episodes. Furthermore, these studies have demonstrated that the 103 empiric treatment of neonatal sepsis currently recommended by WHO, which includes a narrow-104 105 spectrum  $\beta$ -lactam antibiotic in combination with gentamicin as a first line regimen and a 3<sup>rd</sup> generation cephalosporin as a second line regimen [11], is increasingly compromised by high 106 drug resistance rates, particularly due to the high prevalence of ESBLs and of aminoglycoside 107 modifying enzymes (AMEs). Findings from these recent studies extend data from several 108 109 previous reports from LMICs where extremely high rates of resistance to amoxicillin (80%), gentamicin (60%) and third-generation cephalosporins (>80%) were observed [12-17]. 110

111 The NeoOBS study [6, 18] was a prospective, multicenter, observational cohort study 112 investigating the management of neonatal sepsis in several countries, aiming to inform and 113 enhance the design of the currently recruiting Global Antibiotic Research & Development 114 Partnership (GARDP) - sponsored NeoSep1 antibiotic trial (ISRCTN48721236). The trial is 115 investigating new antibiotic regimens for the treatment of neonatal sepsis that have activity 116 against priority neonatal bacterial pathogens and have the potential to be available for wide use 117 in LMICs.

Three generic antibiotics, amikacin, flomoxef and fosfomycin were selected that met the criteria for consideration in the trial [19], and their potential to be used in novel combined empirical regimens was assessed by a dynamic hollow-fiber infection model (HFIM) and by checkerboard assays [20-22]. The three combinations, fosfomycin-amikacin, fosfomycin-flomoxef and flomoxef-amikacin exhibited synergistic interactions measured by both bactericidal killing and the prevention of emergence of resistance.

124 The NeoOBS microbiology sub-study aimed to determine the level of antibiotic susceptibility of

125 MDR Gram-negative bacteria to currently used antibiotics and to the novel drug combinations

included in the NeoSep1 trial.

127

128 Material and Methods

129 <u>Study setting</u>

130 A prospective observational clinical study of neonatal sepsis was conducted between 2018 and

131 2020 at 19 hospitals across 11 predominantly LMIC countries from five WHO regions (Africa,

America, Europe, Southeast Asia, and Western Pacific) [6]. Hospitalized infants <60 days of age

133 with an episode of clinically suspected sepsis were eligible for enrollment.

134

135 <u>Strain collection and characterization of isolates</u>

136 The Laboratory of Medical Microbiology (LMM) at the University of Antwerp received bacterial

137 isolates from blood and cerebrospinal fluid (CSF) samples of neonates with culture-confirmed

sepsis from 13 participating sites in 9 countries (Supplementary Table 1). LMM did not obtain

139 bacterial isolates from 3 sites from India and 3 from China. All the participating sites followed a

140 well-established microbiological protocol for collection, storage and shipment of the isolates to

141 the central laboratory [18]. At LMM, species identification was verified using Microflex LT

142 MALDI-TOF MS (Bruker Daltonics) and the MALDI Biotyper IVD reference library (2021).

143

#### 144 Selection of the isolates for inclusion in this microbiology study

Identification at species level was confirmed by WGS for 723 out of 1051 bacterial isolates. 145 Gram positive were 303 (Coagulase-negative staphylococci (n=254) and *Staphylococcus aureus*, 146 147 n=49), and 420 were Gram-negative, belonging to 23 different species. Enterobacterales, comprising Klebsiella pneumoniae (n=135), Escherichia coli (n=33), Serratia marcescens 148 (n=34) and Enterobacter cloacae complex (n=27), as well as Acinetobacter baumannii (n=80) 149 as non-fermenters, were the most common pathogens, together accounting for nearly three-150 151 quarters of Gram-negative isolates. The focus of this study was limited to Gram-negative bacteria. 152

For all analyses, the patient's first clinical isolate from blood or CSF was selected. In case of mixed infection, isolates belonging to different species were also included. To avoid analyzing replicates of the same bacterial clone, only isolates displaying different genetic profiles were selected for *in vitro* susceptibility testing. Isolates belonging to a given species for which less than 20 isolates were obtained were not further analyzed.

158

#### 159 DNA isolation and Whole Genome Sequencing (WGS)

Genomic DNA isolation was done using the MasterPure complete DNA and RNA purification 160 kit (Epicentre, Madison, WI, USA). Library and sample preparation were performed using 161 162 Nextera XT sample preparation kit (Illumina) and for sequencing MiSeq (Illumina Inc., USA) was used. The raw data of the sequenced strains were quality checked and trimmed using 163 trimmomatic v0.4.2. The second analysis was performed using BacPipe v.1.2.6 [23]. Built-in 164 tools and databases were used for *de novo* assembly SPAdes (v.3.11.0) and Prokka (v1.11.1) for 165 166 annotation. Assembled contigs were quality checked using checkM [24]. MLST for E. coli [25], 167 K. pneumoniae [26], Enterobacter spp. [27] and Acinetobacter spp. [28] were determined

168 according to MLST schemes of organism-specific reference databases. For core genome 169 multilocus sequence typing (cgMLST), a gene-by-gene approach was utilized by developing a custom scheme for the specific study, assessing allelic loci distances using ChewBBACA [29]. 170 Clonal relatedness was defined as  $\leq 10$  allelic differences between isolates for *A. baumannii* [29] 171 172 and <12 for *Klebsiella* spp. [30]. Trees were visualized using Grapetree [31]. For strains for 173 which phenotypic MIC susceptibility testing was not performed, the presence of one or more resistance genes to the tested antibiotics was used to reflect resistance. 174 In vitro susceptibility testing 175 176 Eighty-seven K. pneumoniae and 21 E. coli isolates representing different genetic profiles were

tested against first- and second- line WHO-recommended regimens (ampicillin, gentamicin and
cefotaxime), as well as piperacillin-tazobactam, meropenem and three antibiotics (flomoxef,
amikacin and fosfomycin) that are under investigation as a potential new regimen in combination.
The activity of fosfomycin was assessed by agar dilution method. All tests were performed
according to the latest guidelines of the EUCAST susceptibility testing standards and
interpretation criteria (https://www.eucast.org/clinical\_breakpoints).

For flomoxef, in the absence of formal EUCAST/CLSI clinical breakpoint, we used an MIC susceptibility breakpoint of  $\leq 1 \text{ mg/L}$ , based on a large retrospective study in patients with bacteremia due to ESBL producers, which reported a more favorable clinical outcome in patients treated with flomoxef when isolate MICs were  $\leq 1 \text{ mg/L}$  compared to those with MICs  $\geq 2 \text{ mg/L}$ [32].

The susceptibility of the isolates to the proposed combination regimens was analyzed based on the novel combination breakpoint thresholds determined by HFIM model and checkerboard assays [20-22]. If flomoxef MIC values are between 1 and 32 mg/L, combination with fosfomycin or amikacin extends flomoxef's spectrum of activity, but only when MIC of the associated drug is in the range of the corresponding MIC breakpoints, i.e.  $\leq$ 32 mg/L for

```
193 fosfomycin and \leq 16 mg/L for amikacin [20, 21]. Success of fosfomycin-amikacin combination
```

- 194 is predicted if the product of the two individual antibiotic MICs is  $\leq 256 \text{ mg/L}$  [R. da Costa,
- 195 personal communication, August 31, 2023].

196

### 197 **Results**

- 198 In total, 420 Gram-negative bacterial isolates were received. The five most common identified
- 199 species were: K. pneumoniae (n=135), A. baumannii (n=80), E. coli (n=34), S. marcescens
- 200 (n=33) and Enterobacter cloacae complex (ECC) (n=27). These 309 Gram-negative isolates
- were obtained from 295 patients. The remaining 111/420 GNB isolates belonged to 18 different
- bacterial species were represented by less than 20 isolates each. The distribution of the five major
- 203 GNB isolates per sites is shown in Figure 1.





205



207 species analyzed by site.

208 (n=309, one isolate per species per patient only, following removal of duplicates).

209 (number of isolates correlates with the number of neonates, except for the following sites: TH13

210 (13 neonates - 14 isolates), SA12 (46 neonates - 51 isolates), SA11 (51 neonates - 56 isolates),

SA10 (75 neonates - 77 isolates) and BR2 (5 neonates - 6 isolates)).

212

## 213 Antibiotic susceptibility testing and resistance mechanisms

Ampicillin/gentamicin regimen had low rates of coverage, with 32% (34/108) of the isolates

susceptible, and only 22% (24/108) susceptible to cefotaxime (Supplementary Table 2).

216 K. pneumoniae was the species with highest rates of resistance due to the high prevalence of

ESBLs and of AMEs, found in 74% (64/87) and 63% (55/87) of the isolates, respectively. The

rates of susceptibility to piperacillin-tazobactam differed between *K. pneumoniae* (35%) and *E.* 

219 coli (67%) due to the frequent occurrence of the  $bla_{OXA-1}$  gene among K. pneumoniae isolates.

220 Carbapenem resistance was almost exclusive to K. pneumoniae, with 30% (26/87) strains

resistant to meropenem versus 5% (1/21) of *E. coli*. The most prevalent carbapenem resistance

222 genes were NDM-like (81%; n=21/26), followed by OXA-48-like (11%; n=3/26).

223 Susceptibility rates to flomoxef (71%) and amikacin (70%) were comparable to those observed 224 for meropenem (75%) in the subset of 108 isolates with available MIC results. Flomoxef displayed good activity against ESBL-producing Enterobacterales (ESBL-PE) and resistance to 225 this agent was due to class C β-lactamases and carbapenemases. Among the aminoglycosides, 226 amikacin showed the best activity against ESBL-PE, since it was not affected by common AMEs 227 (AAC(3)-II, ANT(2')-I), which are known to modify gentamicin. Fosfomycin showed the 228 229 strongest antibacterial activity with 90% of the phenotypically tested isolates being susceptible 230 to this antibiotic. An almost perfect match (106/108) was found between susceptibility and 231 resistance phenotypes and genotypes for all beta-lactams, including broad-spectrum penicillins, cephalosporins and carbapenem drugs, as well as for aminoglycosides. All ESBLs, AmpC and 232 233 carbapenem resistance genes detected by genotyping correctly predicted strain susceptibility 234 patterns, except for one K. pneumoniae isolate carrying the  $bla_{NDM-1}$  gene but found to be

235 susceptible to meropenem (MIC of 0.06 mg/L). For aminoglycosides, all strains carrying 236 resistance genes coding for modifying enzymes to gentamicin and/or to amikacin were confirmed as resistant to these drugs by MIC testing. All strains coding for 16S rRNA methylase genes 237 238 displayed high level resistance to gentamic n and to amikac (MIC > 256 mg/L for both agents). 239 One K. pneumoniae isolate displayed high-level resistance to amikacin (MIC >256 mg/L) but 240 did not contain a resistance gene that accounts for resistance to amikacin. Among the 11 fosfomycin-resistant strains, only two carried the gene encoding the fosfomycin-modifying 241 242 enzyme (*fosA3* in one *E. coli* isolate with a fosfomycin of MIC >512 mg/L and *fosA5* in one *K*. 243 pneumoniae isolate with an MIC of 64 mg/L). Besides fosA3 and fosA5, genes coding other 244 fosfomycin-modifying enzymes (*fosB*, *fosC*, *fosX*) were not found in the resistant strains. Also, no mutations of cell-wall transport systems (glpT and uhpT), their respective regulatory genes 245 246 (cyaA and ptsI) nor murA targets were present in any of these strains.

247 The rates of susceptibility to the proposed new regimens were assessed using the novel combination breakpoint thresholds determined by HFIM assays [20-22]. For Enterobacterales 248 isolates for which MIC determination was performed, prediction of susceptibility to at least one 249 250 antibiotic combination was 77/108 (71%) isolates for flomoxef-amikacin, 85/108 (79%) for fosfomycin-amikacin and 82/108 (76%) for flomoxef-fosfomycin compared to 34/108 (31%) for 251 252 ampicillin-gentamicin and 24/108 (22%) for cefotaxime (Table 1 and Supplementary Table 2). The three new combinations exhibited strong activity against ESBL-producing E. coli and K. 253 254 pneumoniae isolates (excluding those strains producing an AmpC cephalosporinase and 255 carbapenemase in addition to ESBL) and an excellent coverage with flomoxef-amikacin and 256 flomoxef-fosfomycin of 100% (n=52/52) and 92% (n=48/52) with fosfomycin-amikacin 257 combinations.

### **Table 1. Susceptibility of 108 Enterobacterales isolates to different combination regimens**

Enterobacterales* isolates tested	FOS°/FLX°	FOS/AMK°	FLX/AMK			
for MIC determination	N (% coverage)					
Cefotaxime-S (n=24)	24 (100)	23 (96)	24(100)			
ESBL-neg Enterobacterales						
Cefotaxime-R/meropenem-S (n=58)	55 (95)	52 (90)	53 (91)			
ESBL-pos/Carba-Neg Enterobacterales	52 (100)	48 (92)	52 (100)			
( <i>n</i> =52)						
AmpC-pos/Carba-Neg Enterobacterales (n=6)	3 (50)	4 (67)	1 (17)			
Meropenem-R (n=26)	3 (12)	10 (38)	0 (0)			
Carba-Pos Enterobacterales**						
Total number of isolates (n=108)	82 (76)	85 (79)	77 (71)			

## 260 based on the novel combination breakpoint thresholds [20-22]

261 *\* Klebsiella pneumoniae* (n=87), *Escherichia coli* (n=21)

<sup>°</sup> FOS: fosfomycin, FLX: flomoxef, AMK: amikacin

\*\* Among the 26 meropenem-resistant, carbapenemase-producing Enterobacterales isolates, 21
 were concomitantly ESBL-producing and 5 were ESBL-negative.

265

266 Susceptibility of *S. marcescens* and ECC was predicted by the presence of resistance genes. Both

267 species harbored genes coding for inducible chromosomal AmpC and displayed resistance to

cefotaxime, as well as to flomoxef alone. In addition, genes coding for ESBLs were observed in

269 6/33 (18%) of *S. marcescens* and 10/27 (37%) of ECC isolates. Resistance to gentamicin was

270 predicted in 4/33 (12%) of *S. marcescens* and in 10/27 (37%) of ECC.

271 The activity of amikacin was predicted to cover 91% of *S. marcescens* and 96% of ECC isolates,

since genes coding for AMEs or for 16SrRNA methylase genes that confer resistance to this

antibiotic were not widespread. Carbapenem resistance was predicted to be low, as only one

isolate per species was found to carry an NDM-like gene.

Among A. baumannii isolates, 91% (73/80) harbored OXA-like carbapenemase genes (mostly

276 OXA-23 and OXA-58) and 45% (36/80) co-harbored NDM-1 always in association with OXA-

23, as well as resistance genes to several other classes of antimicrobials, including the 16S rRNA
methylase genes, that confers high-level resistance to all aminoglycosides for clinical use.

279

#### 280 Characterization of Klebsiella pneumoniae

281 K. pneumoniae isolates were found in all 13 sites, and WGS analysis revealed high genetic diversity with a total of 56 different sequence types (STs) found among the 135 isolates obtained. 282 283 Fifty-seven isolates belonging to 12 STs were predicted to be MDR, based on the presence of 284 acquired drug resistance genes to 3 or more classes of antimicrobial agents. These MDR K. 285 pneumoniae clones were isolated at all sites but with different geographic distribution of STs 286 (Table 2). For instance, the predominant STs in South African sites were ST39, ST17 and ST14, 287 while ST15 and ST147 were found in Vietnam and Bangladesh, respectively. As illustrated in 288 Table 2, *K. pneumoniae* belonging to different STs were often co-circulating at different sites. 289 290 291 292 293 294 295

296

#### Table 2. Distribution of the 12 most prevalent MDR STs of *K. pneumoniae* by site.

299

						Se	equence	types*	:				
Site	ST39	ST17	ST14	ST307	ST37	ST11	ST147	ST15	ST101	ST14- 1LV	ST15- 1LV	ST20	Total
BA1	1					1	3				1		6
BR2						2							2
BR3													0
GR4					1								1
IT8													0
KE9		1											1
SA10			3		1								4
SA11	12	3	1										16
SA12	1	7	5	2									15
TH13		1		2									3
TH14													0
UG15				1	1					1			3
VI16					1			3	1			1	6
Total	14	12	9	5	4	3	3	3	1	1	1	1	57

<sup>300</sup> 

\*The presence of more than one isolate belonging to the same sequence type at a given siteindicates clonal spread

303

304 CgMLST revealed that isolates of the same ST found at different sites could be delineated in

different clones (Figure 2). This analysis had, as expected, a much higher discriminatory power

than classical multilocus sequence typing and it allowed the detection of distinct clones within a

single ST, most notably for ST39, ST14 and ST17.



309

Figure 2. Minimum spanning tree of cgMLST analysis of MDR clones of *K. pneumoniae* 

#### 311 (n=57) showing specific local site clustering.

Left: ST based clustering Right: Site based clustering. The white circles represent publicreferences.

314

In total, 83% (112/135) of *K. pneumoniae* isolates carried one or several ESBL genes encoding

resistance to extended spectrum cephalosporins; this was confirmed phenotypically for 65/87

317 isolates (44 ESBL only and 21 in association with carbapenamase) tested phenotypically. ESBL

318 coding genes were widely distributed and found in isolates from 12/13 sites; the  $bla_{\text{CTX-M-15}}$  gene

319 was the most prevalent ESBL, present in 96 isolates at 10 sites. Other less frequently found ESBL

320 genes were *bla* CTX-M-14 (in 7 isolates), *bla* CTX-M-27 (in 2 isolates) both at site VI16 in Vietnam,

321 *bla*<sub>SHV</sub> (in 5 isolates) and *bla*<sub>TEM</sub> (in 2 isolates).

322 On the contrary, only six isolates carried AmpC genes, *bla*<sub>MOX-2</sub> (n=3, site GR4) and *bla*<sub>DHA-1</sub>

323 (n=3 from BA1, TH13 and VI16).

All strains with carbapenemase coding genes were phenotypically resistant. These strains were

found at 7 sites across five countries (Figure 3). The most frequent carbapenem resistance gene

was  $bla_{NDM}$  being identified in 31/135 (23%) of K. pneumoniae isolates. Among the different

variants, *bla*<sub>NDM-1</sub> was the most prevalent (n=20) but other alleles (*bla*<sub>NDM-4</sub> and *bla*<sub>NDM-5</sub>) were
also found. As known from the epidemiology of carbapenemase producers, specific carbapenem
resistance genes were associated with the geographic areas in which the isolates were found.
Despite the small number of isolates, KPC producing strains were mostly found in Brazil, those
carrying OXA-48-like carbapenemase in Bangladesh (BA1) and South Africa (SA11) and those
with NDM-4 and NDM-5 in South-East Asia (VI16) and Asia (BA1) (Figure 3).

333





Figure 3. Distribution of carbapenem resistance genes of *K. pneumoniae* isolates (n=135)

336 by site.

337 (n) = total number of *K. pneumoniae* isolates per site. Sites that collected *K. pneumoniae* isolates 338 lacking any carbapenem resistance genes are not shown in this figure (UG15 n=5, GR4 n=4, KE9 339 n=4, IT8 n=3, BR3 n=3 and TH14 n=2).

340

Acquired aminoglycoside resistance genes were found in 122/135 (90%) *K. pneumoniae* isolates

- 342 (Figure 4), usually in association with ESBL- and/or with carbapenemase-coding genes. In
- particular the aac(3)-II genes which confers resistance to gentamicin, were frequently present
- 344 (n=90; 67%), most often in association with *bla*<sub>CTX-M-15</sub> ESBL gene (n=78). Other genes IIke



- found only in 6 isolates at three sites, BA1, GR4 and IT8 (n=2 each). Genes coding for 16S rRNA
- 347 methylases (*armA*, *rmtB*, *rmtC*, *rmtF*), which are known to confer resistance to all clinically used
- aminoglycosides, were identified in 23 isolates from 5 sites (BA1, SA10, SA11 SA12 and VI16)
- 349 (Figure 4). The 16S rRNA methylase genes were carried only by carbapenemase-producing
- 350 isolates, mostly NDM-producers.
- 351



#### Figure 4. Distribution of aminoglycoside resistance genes of *K. pneumoniae* isolates (n=135) by site.

(n) = total number of *K. pneumoniae* isolates per site found. Two sites that collected *K. pneumoniae* isolates (BR3 n=3 and TH14 n=2) but without aminoglycoside resistance genes being detected are not represented in this figure. Several isolates were carrying more than one resistance gene to a given class of antimicrobial agents. Other aminoglycoside resistance genes: *aadA, aph(6')-I* (streptomycin resistance) and *aph(3')-I* (neomycin/kanamycin resistance) were very frequent but are not represented in this figure due to their lack of clinical relevance in humans.

361

### 362 Characterization of E. coli

- 363 Thirteen different *E. coli* STs were identified. ST1193 (n=13, 38%) was the most abundant in
- isolates from Vietnam (VI16, n=5) and one site in South Africa (SA11, n=4). The second most
- prevalent ST type was ST131 (n=5, 15%), reported from two sites in South Africa (SA10, n=1

and SA12, n=2), Thailand (TH13, n=1) and Vietnam (VI16, n=1).

- 367 Compared to K. pneumoniae, E. coli isolates carried fewer antibiotic resistance genes. Thirty-
- eight percent of the isolates (13/34) harbored an ESBL gene, mostly *bla*<sub>CTX-M-27</sub> (n=8) and *bla*<sub>CTX-</sub>
- 369  $M_{-15}$  (n=5) genes. Only one isolate carried a *bla*<sub>KPC-2</sub> carbapenem resistance gene (site VI16) and
- 370 one with AmpC gene ( $bla_{CMY-2}$ , site TH13).
- 371 Aminoglycoside resistance genes were detected in 9 E. coli isolates from 5 sites. Genes encoding
- 372 AMEs modifying only gentamicin (*aac*(3)-*II* and *ant*(2')-*Ia*) were observed in 7 isolates and were
- found in association with ESBL genes mostly in ST131 or in ST1193. Furthermore, two E. coli
- 374 strains from site VI16 carried the *rmtB* 16S RNA methylase gene leading to resistance to all

aminoglycosides including amikacin.

376

### 377 Characterization of A. baumannii

In A. baumannii, 13 different sequence types were identified, with two of them predominant: 378 ST1 (n=36) and ST2 (n=24). These two STs represent the two major international pandemic 379 380 lineages, GC1 and GC2, respectively. Two sites from South Africa (SA10 and SA12) accounted for 80% of the A. baumannii isolates. Two different clusters could be delineated within ST1 and 381 ST2 each (Figure 5). While the ST2 strains were grouped in two distinct clusters and differed 382 between sites SA10 and SA12, the ST1 strains of these two sites were also grouped in two 383 384 different clusters, but closely related to each other with a small allelic loci distance (Figure 5). 385 Other sporadic STs not associated with pandemic lineages were found at single sites.



387 Figure 5. Minimum spanning tree from A. baumannii genomes (n=80) by cgMLST

388 sequence types (STs).

Left: The MLST groups (Pasteur scheme). Right: The sequence type diversity by site. White
circles indicate the public references.

A. baumannii isolates displayed a very extensive drug resistance profile. Carbapenemase-392 393 producing A. baumannii isolates were found in 8 sites in 5 countries in Asia and Africa (Figure 6).  $Bla_{OXA23}$  was the most frequently present carbapenem resistance gene, present in 64/80 (80%) 394 395 of the isolates and nearly half of the OXA-23-producers (n=36; 45%) co-carried bla<sub>NDM-1</sub>. Ten 396 isolates (13%), seven of which from site SA12, were carrying a  $bla_{OXA-58}$  gene (Figure 6). All 397 ST1 isolates from sites SA10, SA11 and SA12 in South Africa always carried the  $bla_{NDM-1}$  and 398 *bla*<sub>OXA-23</sub> genes. On the other hand, strains belonging to ST2 carried *bla*<sub>OXA-23</sub> alone and never in 399 association with  $bla_{NDM-1}$ . Most of the  $bla_{OXA-58}$  positive isolates (n=10) were associated with 400 ST243 and were found almost exclusively at site SA12 (n=7; 70%).



#### 403 Figure 6. Distribution of carbapenem resistance genes in *A. baumannii* isolates (n=80) by site.

Site UG15 (n=1) not represented in the chart since one unique *A. baumannii* isolate lacking any
 acquired carbapenemase producing genes.

406

402

More than 90% (74/80) of the *A. baumannii* isolates harbored one or several resistance
mechanisms to all aminoglycosides including amikacin (Figure 7). The *armA* rRNA 16S
methylase gene (in 53/80 strains, 62%) often in association with *aac(3)-Ia* (in 35/80 strains,
44%), was the most common aminoglycoside resistance mechanism.





Figure 7. Distribution of aminoglycoside resistance genes of *A. baumannii* isolates (n=80)
per site.

414 (n) = total number of A. baumannii isolates collected per site. aph(3')-VI (n=2) and aph(3')-VIa

415 (n=17) grouped together. Several isolates were carrying more than one resistance gene to a

416 given class of antimicrobial agents.

417

#### 418 Characterization of *Enterobacter cloacae* complex (ECC)

419 ECC isolates (n=27) were collected at 12 sites in 8 countries with different subspecies occurring

420 at the different sites. *E. hormaechei* (n=15) was the most common species found at 8 sites; *E.* 

421 roggenkampii (n=4) at two and *E. asburiae* (n=3) at 3 sites. Antimicrobial resistance in ECC is

422 partly due to intrinsic chromosomal genes. All strains had in their core genome different alleles

423 of *bla*<sub>ACT</sub>, an intrinsic AmpC gene that when overexpressed leads to resistance to expanded

424 spectrum cephalosporins.

425 Multiple acquired resistance genes were found in 10/27 (37%) of the ECC isolates. All of these

426 multidrug resistant strains were identified genetically as *E. hormaechei*. These strains belong to

five different ST types including the well-known ST68 and ST78 MDR lineages. Nine of the 10 ESBL-producing *E. hormaechei* isolates carried a  $bla_{CTX-M-15}$  and one a  $bla_{SHV-12}$  gene. Other resistance genes that were frequently found in association with ESBLs were  $bla_{OXA-1}$  gene (resistance to piperacillin-tazobactam) and aac(3)-*II* coding genes (resistance to gentamicin). One of the 10 strains collected at site BA1 was also carrying a  $bla_{NDM-1}$  gene and a *rmtB* 16S

- 432 rRNA methylase gene rendering it almost pan-resistant.
- 433

## 434 Characterization of Serratia marcescens

435 Thirty-three Serratia marcescens isolates were collected from 7 sites in 6 countries, majority

436 (n=19; 58%) from the two South African sites. The cgMLST analysis highlighted the diversity

437 of the *S. marcescens* isolates, between the different sites but also within single sites.

438 Genes coding for ESBLs,  $bla_{VEB-5}$  (n=2),  $bla_{CTX-M-14}$  (n=2) and  $bla_{CTX-M-15}$  (n=2) were found in 6

439 (18%) isolates in Vietnam (n=3), Bangladesh (n=2), and Thailand (n=1). One isolate from

440 Vietnam harbored a  $bla_{NDM-5}$  carbapenem resistance gene.

16S rRNA methylase genes (*armA* (n=2); *rmtB* (n=1)) were found in three isolates at two sites,
BA1 and VI16.

443

### 444 Discussion

Three generic antibiotics, flomoxef, amikacin and fosfomycin, were evaluated in novel combinations as new empiric carbapenem-sparing regimens for the treatment of neonatal sepsis, exhibited very good activity against the majority of these Enterobacterales isolates. The NeoOBS clinical study documented Gram-negative bacteria as the most common causative pathogens in neonatal sepsis [6], which is consistent with recent literature in LMICs [33]. The most frequently isolated species were *K. pneumoniae* and *A. baumannii*, a finding which is also in line with data

451 by others from several single and multicenter studies of neonatal sepsis in LMICs [4, 5, 7, 9, 34-36]. A. baumannii isolates were predicted to be extremely drug-resistant as they harbored a large 452 array of genes conferring resistance to almost all classes of antibiotics, leaving colistin as the 453 only therapeutic option for neonatal sepsis caused by this organism. Among Enterobacterales, 454 resistance to  $\beta$ -lactams was due to the widespread distribution of ESBLs, especially among K. 455 456 pneumoniae (79%) and E. coli (38%) isolates. Piperacillin-tazobactam, that provides partial 457 ESBL/pseudomonal coverage and was commonly used as empirical treatment by some hospitals [6], had moderate antibacterial activity against E. coli (susceptibility of 67%) but low activity 458 459 against K. pneumoniae (susceptibility of 35% only), due to the widespread distribution of blaoxA-1. These high rates of antimicrobial resistance have been translated to the increased use of 460 meropenem for treatment of these patients with sepsis at these sites. However, in this study 461

462 resistance to meropenem was also observed in approximately 30% of *K. pneumoniae* isolates.

All isolates in this study showed wide genetic diversity, especially K. pneumoniae isolates, with 463 56 different STs in 135 isolates. Multidrug resistant strains belonged to different lineages and 464 clones. Most of these isolates belong to multidrug-resistant international lineages that are already 465 widely reported in both adults and neonates, and are known to be associated with nosocomial 466 467 outbreaks and endemic hospital settings [37-39]. Besides their ability to spread through clonal 468 expansion, these MDR lineages are also known to carry several plasmids, transposons and other 469 mobile genetic elements that allow them to acquire and spread antimicrobial resistance within and across different bacterial species [40]. 470

In *E. coli*, ST131 and ST1193 accounted as the most frequent STs in the NeoOBS study. This is
in line with a recent epidemiological study which found that next to ST131, ST1993 is the second
most widely globally distributed MDR clone recorded to date [41]. Interestingly, we found that *E. coli* ST1193 was also largely distributed in different sites from Vietnam to Kenya, Uganda
and South Africa, highlighting the expansion of this lineage also on the African continent.

476 Multi-drug resistant A. baumannii strains were unevenly distributed at 8 sites, but found in large

477 numbers at only two of the participating sites (SA10 and SA12).

*A. baumannii* has emerged during the last decade as a major difficult to treat nosocomial bacterial
pathogen which is often linked with outbreaks or endemic contexts in healthcare settings. Once
established, this organism can persist in the healthcare environment and is extremely difficult to
eradicate [42]. Unlike *K. pneumoniae* and *E. coli* which showed high genetic diversity, *A. baumannii* isolates were less diverse and mostly belonged to the two dominant pandemic
international clonal groups (CG1 and CG2) known to occur in a limited number of sites, mostly
in South Africa.

Susceptibility of *S. marcescens* and ECC was inferred from genotyping of resistance genes. Both species had inducible chromosomal AmpC genes and showed resistance to the WHO second-line cephalosporin regimen (cefotaxime/ceftriaxone) as well as to flomoxef alone. It is well known from the literature that derepressed mutants can be selected in AmpC inducible species during therapy with these agents and lead to the development of resistance and clinical failure, especially in invasive infection caused by *Enterobacter cloacae* complex [43].

Although the study recruited over 3200 neonates, the limitations of this study mainly relate to 491 492 the relatively small number of samples obtained, especially from sites where lower number of patients were enrolled. Besides differences in the prevalence and distribution of neonatal sepsis 493 494 pathogens, variation in blood culture positivity rates between centers was also observed [6], 495 possibly indicating differences in the collection and/or performance of microbiological methods 496 used locally. The majority of neonatal units participating in this study were from tertiary hospitals 497 in urban areas, so the burden of AMR may not be representative for district hospitals. These 498 elements represent an important bias in most AMR studies in low-resource settings, where the 499 need for high-quality microbiology means that certain settings may be overrepresented.

500

# 501 Conclusion

502	The NeoOBS study showed wide variety of bacterial species as a cause of neonatal sepsis, many
503	of which carried multiple resistance genes. Among Gram-negative isolates, K. pneumoniae was
504	the most predominant species widely distributed among the sites. Many of the isolates from our
505	study were resistant to the first and second line WHO treatments, mostly because of the very
506	frequent occurrence of ESBLs. New agents that can target these pathogens are urgently needed.
507	The three novel antibiotic combinations, fosfomycin-flomoxef, fosfomycin-amikacin and
508	flomoxef-fosfomycin showed high activity especially against ESBL producing E. coli and
509	Klebsiella pneumoniae isolates. Our study supports the evaluation of these combinations in the
510	NeoSep1 trial, for treatment of neonatal sepsis.

## 512 **References**

- Antimicrobial Resistance, C., Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet, 2022. 399(10325): p. 629-655.
- 515 2. Organization, W.H., *Global report on the epidemiology and burden of sepsis: current evidence, identifying gaps and future directions.* 2020.
- 517 3. Gan, M.Y., et al., Contemporary Trends in Global Mortality of Sepsis Among Young
  518 Infants Less Than 90 Days: A Systematic Review and Meta-Analysis. Front Pediatr, 2022.
  519 10: p. 890767.
- Sands, K., et al., *Characterization of antimicrobial-resistant Gram-negative bacteria that cause neonatal sepsis in seven low- and middle-income countries.* Nat Microbiol, 2021.
  6(4): p. 512-523.
- 523 5. Investigators of the Delhi Neonatal Infection Study, c., *Characterisation and*524 *antimicrobial resistance of sepsis pathogens in neonates born in tertiary care centres in*525 *Delhi, India: a cohort study.* Lancet Glob Health, 2016. 4(10): p. e752-60.
- 526 6. Russell, N.J., et al., Patterns of antibiotic use, pathogens, and prediction of mortality in
  527 hospitalized neonates and young infants with sepsis: A global neonatal sepsis
  528 observational cohort study (NeoOBS). PLoS Med, 2023. 20(6): p. e1004179.
- 529 7. Okomo, U., et al., Aetiology of invasive bacterial infection and antimicrobial resistance
  530 in neonates in sub-Saharan Africa: a systematic review and meta-analysis in line with
  531 the STROBE-NI reporting guidelines. Lancet Infect Dis, 2019. 19(11): p. 1219-1234.
- 532 8. Ullah, O., et al., Antibiotic Sensitivity pattern of Bacterial Isolates of Neonatal Septicemia
  533 in Peshawar, Pakistan. Arch Iran Med, 2016. 19(12): p. 866-869.
- Hamer, D.H., et al., *Etiology of bacteremia in young infants in six countries*. Pediatr Infect
  Dis J, 2015. 34(1): p. e1-8.
- Dramowski, A., A. Madide, and A. Bekker, *Neonatal nosocomial bloodstream infections at a referral hospital in a middle-income country: burden, pathogens, antimicrobial resistance and mortality.* Paediatr Int Child Health, 2015. **35**(3): p. 265-72.
- Fuchs, A., et al., *Reviewing the WHO guidelines for antibiotic use for sepsis in neonates and children.* Paediatr Int Child Health, 2018. 38(sup1): p. S3-S15.
- Labi, A.K., et al., *Neonatal bloodstream infections in a Ghanaian Tertiary Hospital: Are the current antibiotic recommendations adequate?* BMC Infect Dis, 2016. 16(1): p. 598.
- Bandyopadhyay, T., et al., *Distribution, antimicrobial resistance and predictors of mortality in neonatal sepsis.* J Neonatal Perinatal Med, 2018. 11(2): p. 145-153.
- Jajoo, M., et al., *Alarming rates of antimicrobial resistance and fungal sepsis in outborn neonates in North India.* PLoS One, 2018. 13(6): p. e0180705.
- Yadav, N.S., et al., *Bacteriological profile of neonatal sepsis and antibiotic susceptibility pattern of isolates admitted at Kanti Children's Hospital, Kathmandu, Nepal.* BMC Res
  Notes, 2018. 11(1): p. 301.
- Pokhrel, B., et al., *Bacteriological profile and antibiotic susceptibility of neonatal sepsis in neonatal intensive care unit of a tertiary hospital in Nepal.* BMC Pediatr, 2018. 18(1):
  p. 208.
- 553 17. Chaurasia, S., et al., Neonatal sepsis in South Asia: huge burden and spiralling
  554 antimicrobial resistance. BMJ, 2019. 364: p. k5314.
- Riddell, A., et al., Challenges in the Implementation of the NeoOBS Study, a Global
  Pragmatic Observational Cohort Study, to Investigate the Aetiology and Management of
  Neonatal Sepsis in the Hospital Setting. Antibiotics (Basel), 2023. 12(5).
- Darlow, C.A., et al., *Potential Antibiotics for the Treatment of Neonatal Sepsis Caused by Multidrug-Resistant Bacteria*. Paediatr Drugs, 2021. 23(5): p. 465-484.

20. Darlow, C.A., et al., Amikacin Combined with Fosfomycin for Treatment of Neonatal 560 561 Sepsis in the Setting of Highly Prevalent Antimicrobial Resistance. Antimicrob Agents Chemother, 2021. 65(7): p. e0029321. 562 563 21. Darlow, C.A., et al., Flomoxef and fosfomycin in combination for the treatment of neonatal sepsis in the setting of highly prevalent antimicrobial resistance. J Antimicrob 564 565 Chemother, 2022. 77(5): p. 1334-1343. 22. Darlow, C.A. and W. Hope, Flomoxef for neonates: extending options for treatment of 566 567 neonatal sepsis caused by ESBL-producing Enterobacterales. J Antimicrob Chemother, 2022. **77**(3): p. 711-718. 568 23. Xavier, B.B., et al., BacPipe: A Rapid, User-Friendly Whole-Genome Sequencing 569 Pipeline for Clinical Diagnostic Bacteriology. iScience, 2020. 23(1): p. 100769. 570 24. Parks, D.H., et al., CheckM: assessing the quality of microbial genomes recovered from 571 isolates, single cells, and metagenomes. Genome Res, 2015. 25(7): p. 1043-55. 572 573 25. Wirth, T., et al., Sex and virulence in Escherichia coli: an evolutionary perspective. Mol Microbiol, 2006. 60(5): p. 1136-51. 574 Diancourt, L., et al., Multilocus sequence typing of Klebsiella pneumoniae nosocomial 575 26. isolates. J Clin Microbiol, 2005. 43(8): p. 4178-82. 576 27. Jolley, K.A. and M.C. Maiden, BIGSdb: Scalable analysis of bacterial genome variation 577 at the population level. BMC Bioinformatics, 2010. 11: p. 595. 578 579 28. Diancourt, L., et al., The population structure of Acinetobacter baumannii: expanding multiresistant clones from an ancestral susceptible genetic pool. PLoS One, 2010. 5(4): 580 p. e10034. 581 Fitzpatrick, M.A., E.A. Ozer, and A.R. Hauser, Utility of Whole-Genome Sequencing in 29. 582 Characterizing Acinetobacter Epidemiology and Analyzing Hospital Outbreaks. J Clin 583 Microbiol, 2016. 54(3): p. 593-612. 584 585 30. Kluytmans-van den Bergh, M.F., et al., Whole-Genome Multilocus Sequence Typing of Extended-Spectrum-Beta-Lactamase-Producing Enterobacteriaceae. J Clin Microbiol, 586 2016. 54(12): p. 2919-2927. 587 31. Zhou, Z., et al., GrapeTree: visualization of core genomic relationships among 100,000 588 bacterial pathogens. Genome Res, 2018. 28(9): p. 1395-1404. 589 32. Lee, C.H., et al., Relation between flomoxef minimum inhibitory concentrations and 590 591 clinical outcomes of patients treated with flomoxef for Enterobacteriaceae bacteremia. 592 Infect Drug Resist, 2018. 11: p. 2471-2480. 33. Wen, S.C.H., et al., Gram-negative neonatal sepsis in low- and lower-middle-income 593 594 countries and WHO empirical antibiotic recommendations: A systematic review and 595 meta-analysis. PLoS Med, 2021. 18(9): p. e1003787. van Staaden, H., C. Hendricks, and K. Spicer, Bacteraemia and antibiotic sensitivity in a 34. 596 597 tertiary neonatal intensive care unit. S Afr J Infect Dis, 2021. 36(1): p. 195. 598 35. Pillay, D., et al., Neonatal sepsis in a tertiary unit in South Africa. BMC Infect Dis, 2021. **21**(1): p. 225. 599 Mulinganya, G.M., et al., Etiology of Early-Onset Neonatal Sepsis and Antibiotic 600 36. 601 Resistance in Bukavu, Democratic Republic of the Congo. Clin Infect Dis, 2021. 73(4): p. e976-e980. 602 37. Safavi, M., et al., Global genotype distribution of human clinical isolates of New Delhi 603 metallo-beta-lactamase-producing Klebsiella pneumoniae; A systematic review. J Glob 604 Antimicrob Resist, 2020. 23: p. 420-429. 605 606 38. Mbelle, N.M., et al., Pathogenomics and Evolutionary Epidemiology of Multi-Drug 607 Resistant Clinical Klebsiella pneumoniae Isolated from Pretoria, South Africa. Sci Rep, 608 2020. **10**(1): p. 1232.

- 609 39. Osei Sekyere, J. and M.A. Reta, Genomic and Resistance Epidemiology of Gram610 Negative Bacteria in Africa: a Systematic Review and Phylogenomic Analyses from a
  611 One Health Perspective. mSystems, 2020. 5(6).
- 40. David, S., et al., Integrated chromosomal and plasmid sequence analyses reveal diverse
  modes of carbapenemase gene spread among Klebsiella pneumoniae. Proc Natl Acad Sci
  U S A, 2020. 117(40): p. 25043-25054.
- 41. Pitout, J.D.D., et al., *Escherichia coli ST1193: Following in the Footsteps of E. coli ST131*. Antimicrob Agents Chemother, 2022. 66(7): p. e0051122.
- 617 42. Medioli, F., et al., *Is It Possible to Eradicate Carbapenem-Resistant Acinetobacter*618 *baumannii (CRAB) from Endemic Hospitals?* Antibiotics (Basel), 2022. 11(8).
- 43. Meini, S., et al., *AmpC beta-lactamase-producing Enterobacterales: what a clinician should know.* Infection, 2019. 47(3): p. 363-375.